Immune Checkpoint Inhibitors Market Surpasses $22 Billion in Global Revenue

By: Medtech Ventures llp
 
 
Spread the Word
Listed Under

Tag:
Pharma market research

Industry:
Biotech

Location:
New York City - New York - US

Subject:
Reports

NEW YORK - Jan. 20, 2020 - PRLog -- Immune checkpoint inhibitors market surpassed $22 billion in global revenue in 2019. The market, which took off in 2014 with the launch of Keytruda and Opdivo, the two PD-1 inhibitors from Merck and Bristol-Myers Squibb, has been growing at an average annual growth rate of 65% over the past decade.

Immune checkpoint inhibitors represent some of the most advanced treatments available to patients with cancer and are rapidly becoming the primary first-line treatments for patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic renal cell carcinoma.

Immune Checkpoint Inhibitors – Technology and Market Forecast report offers a helicopter snapshot of current situation in this fast evolving dynamic market. The report is targeted at senior executives in the pharmaceutical, biopharmaceutical, and venture capital industries.

Companies mentioned in the reports include Agenus, AnaptysBio, AstraZeneca, BeiGene, Bristol-Myers Squibb, Eli Lilly, Incyte, Innovent Biologics, Janssen (JnJ),
Jiangsu Hengrui, Junshi Bioscience, MacroGenics, Merck (MSD), Merck KGaA, Novartis, Pfizer, Regeneron, Roche (Genentech) and Sanofi (Genzyme).

Just released report from Medtech Ventures available at:

https://www.researchandmarkets.com/reports/4901457/immune...

Report is also available from Amazon.com:

https://www.amazon.com/dp/B083XTF7Z6

List of Tables & Figures

1.    Top Five Immune Checkpoint Inhibitor Brands by Global Revenue (2019)
2.    Immune System in Action
3.    Checkpoint Mechanism Of Action
4.    Checkpoint Inhibitors Mechanism Of Action
5.    Predictive Biomarkers for Immune Checkpoint Inhibitors
6.    List of FDA Approved Immune Checkpoint Inhibitors
7.    Merck's Keytruda (pembrolizumab) – Global Sales Evolution (2014-2019)
8.    Bristol-Myers Squibb Opdivo (nivolumab) - Global Sales Evolution (2014-2019)
9.    Roche's Tecentriq (Atezolizumab) - Global Sales Evolution (2016-2019)
10.    AstraZeneca's Imfinzi (Durvalumab) - Global Sales Evolution (2017-2019)
11.    Bristol-Myers Squibb's Yervoy (ipilimumab) - Global Sales Evolution (2011-2019)
12.    Regeneron Libtayo (cemiplimab)  - Global Sales Evolution (2018-2019)
13.    Pfizer Bavencio (Avelumab) - Global Sales Evolution (2017-2019)
14.    Global Immune Checkpoint Inhibitors Market Revenue and Growth Rates (2011-2019)
15.    Leading Immune Checkpoint Inhibitors Brands- Global Market Shares (2019)
16.    Leading Immune Checkpoint Inhibitors Companies – Global Market Shares (2019)
17.    Immune Checkpoint Inhibitors - Target Protein Segmentation – 2019
18.    Immune Checkpoint Inhibitors - Geographical Segmentation – 2019
19.    Immune Checkpoint Inhibitors - Clinical Trials Recruitment
20.    Immune Checkpoint Inhibitors in Development or Near Commercialization
21.    Immune Checkpoint Inhibitors -Clinical Trials Landscape
22.    Predictive Biomarkers In Patients Treated With Immune Checkpoint Inhibitors
23.    Immune Checkpoint Inhibitors - Global Market Forecast (2020 - 2025)

Contact
Medtech Wire
***@medtechwire.com
End
Email:***@medtechwire.com Email Verified
Tags:Pharma market research
Industry:Biotech
Location:New York City - New York - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share